Sample no. | Diagnosis | Silverberg grade | FIGO stage | Treatment | Age | Survival |
---|---|---|---|---|---|---|
Chemonaive | Â | Â | Â | Â | Â | Â |
1 | Serous Cystadenoma/ Early Serous Borderline | NA | NA | None | 64 | NA |
2 | Serous Cystadenocarcinoma | NA | III | None | 65 | 1Â year 5Â monthsa |
3 | Serous Papillary Carcinoma | G3 | NA | None | NA | NA |
4 | Papillary Serous Cystadenocarcinoma | G3 | IIIc | None | 48 | 1Â year 6Â monthsa |
5 | Serous Cystadenocarcinoma NOS | G3 | IIIa | None | 51 | 1Â year 3Â monthsa |
6 | Serous Cystadenocarcinoma NOS | G3 | NA | None | 71 | 1Â year 1Â montha |
Recurrent | Â | Â | Â | Â | Â | Â |
1 | Serous Cystadenocarcinoma NOS | G3 | IIc | Carboplatin and Paclitaxel 2 Cycles | 64 | 5Â months until death |
2 | Adenocarcinoma NOS | NA | IV | Carboplatin and Paclitaxel 6 Cycles | 67 | 2Â years 8Â months until death |
3 | Serous Cystadenocarcinoma NOS | G3 | IIIc | Carboplatin/Paclitaxel/ Bevacizumab-VGEF Inhibitor (ICON7 Trial) 18 Cycles | 55 | 5Â years 6Â months until death |
4 | Papillary Serous Cystadenocarcinoma | G3 | IIIc | Carboplatin and Paclitaxel 6 Cycles | 59 | 3Â years 2Â months until death |
Gemicitabine and Cisplatin | ||||||
5 | Papillary Serous Cystadenocarcinoma | G3 | IIIc | Carboplatin/Paclitaxel/BIBF1120- Angiogenesis Inhibitor (OVAR12 Study) | 46 | 3Â years 11Â months ALC |
6 | Serous Cystadenocarcinoma NOS | G3 | IV | Bevacizumab 1Â cycle | 57 | 4Â years 3Â months |
Paclitaxel and Cisplatin 6Â cycles | Â | ALC | ||||
Doxorubicin Pegylated Liposomal 6Â cycles |